TY - JOUR
T1 - Inspiratory muscle weakness in cardiovascular diseases
T2 - Implications for cardiac rehabilitation
AU - Smith, Joshua R.
AU - Taylor, Bryan J.
N1 - Funding Information:
This work was supported by the National Institutes of Health ( K12 HD065987 to JRS). This publication was also made possible through the support of the Mary Kathryn and Michael B. Panitch Career Development Award in Hypertension Research Honoring Gary Schwartz, M.D. (JRS).
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Exercise limitation is a cardinal manifestation of many cardiovascular diseases (CVD) and is associated with poor prognosis. It is increasingly well understood that exercise-based cardiac rehabilitation (CR) is an intervention that portends favorable clinical outcomes, including improvements in exercise capacity. The etiology of exercise limitation in CVD is multifactorial but is typically governed by terminal sensations of pain, fatigue, and/or breathlessness. A known but perhaps underestimated complication of CVD that contributes to breathlessness and exercise intolerance in such patients is inspiratory muscle dysfunction. For example, inspiratory muscle dysfunction, which encompasses a loss in muscle mass and/or pressure generating capacity, occurs in up to ~40% of patients with chronic heart failure and is associated with breathlessness, exertional intolerance, and worse survival in this patient population. In this review, we define inspiratory muscle weakness, detail its prevalence in a range of CVDs, and discuss how inspiratory weakness impacts physiological function and clinical outcomes in patients with CVD often referred to CR. We also evaluate the available evidence addressing the effects of exercise-based CR with and without concurrent specific inspiratory muscle training (IMT) on inspiratory muscle function, general physiological function, and clinical outcomes in patients with CVD. Finally, we consider whether the assessment of global respiratory muscle function should become standard as part of the patient intake assessment for phase II CR programs, giving practical guidance on the implementation of such measures as well as IMT as part of phase II CR.
AB - Exercise limitation is a cardinal manifestation of many cardiovascular diseases (CVD) and is associated with poor prognosis. It is increasingly well understood that exercise-based cardiac rehabilitation (CR) is an intervention that portends favorable clinical outcomes, including improvements in exercise capacity. The etiology of exercise limitation in CVD is multifactorial but is typically governed by terminal sensations of pain, fatigue, and/or breathlessness. A known but perhaps underestimated complication of CVD that contributes to breathlessness and exercise intolerance in such patients is inspiratory muscle dysfunction. For example, inspiratory muscle dysfunction, which encompasses a loss in muscle mass and/or pressure generating capacity, occurs in up to ~40% of patients with chronic heart failure and is associated with breathlessness, exertional intolerance, and worse survival in this patient population. In this review, we define inspiratory muscle weakness, detail its prevalence in a range of CVDs, and discuss how inspiratory weakness impacts physiological function and clinical outcomes in patients with CVD often referred to CR. We also evaluate the available evidence addressing the effects of exercise-based CR with and without concurrent specific inspiratory muscle training (IMT) on inspiratory muscle function, general physiological function, and clinical outcomes in patients with CVD. Finally, we consider whether the assessment of global respiratory muscle function should become standard as part of the patient intake assessment for phase II CR programs, giving practical guidance on the implementation of such measures as well as IMT as part of phase II CR.
KW - Diaphragm
KW - Exercise training
KW - Expiratory muscle strength
KW - Inspiratory muscle training
KW - Respiratory muscle strength
UR - http://www.scopus.com/inward/record.url?scp=85118260252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118260252&partnerID=8YFLogxK
U2 - 10.1016/j.pcad.2021.10.002
DO - 10.1016/j.pcad.2021.10.002
M3 - Review article
C2 - 34688670
AN - SCOPUS:85118260252
SN - 0033-0620
VL - 70
SP - 49
EP - 57
JO - Progress in Cardiovascular Diseases
JF - Progress in Cardiovascular Diseases
ER -